BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples.
Si-Cho Kim 1,# (Graduate student), Jiwon Kim3,# (Graduate student), Da-Won Kim 1 (Graduate student), Yanghee Choi3 (College student), Kyunghyun Park3 (College student), Eun Ju Cho 4 (Professor), Su Jong Yu 4 (Professor), Jeongsil Kim-Ha3 (Professor), Young-Joon Kim 1,2,* (Professor)
1Interdisciplnary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul (03722), Republic of Korea,
2Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul (03722), Republic of Korea,
3Department of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul (05006), Republic of Korea,
4Department of Internal Medicine and Liver Research Institute, Seoul National Universtyt Collge of Medicine, Seoul (03080), Republic of Korea
Hepatocellular carcinoma (HCC) is dangerous cancer that often evades early detection because it is asymptomatic and an effective detection method is lacking. For people with chronic liver inflammation who are at high risk of developing HCC, a sensitive detection method for HCC is needed. In a meta-analysis of The Cancer Genome Atlas pan-cancer methylation database, we identified a CpG island in the USP44 promoter that is methylated specifically in HCC. We developed methylation-sensitive high-resolution melting (MS-HRM) analysis to measure the methylation levels of the USP promoter in cell-free DNA isolated from patients. Our MS-HRM assay correctly identified 40% of patients with early-stage HCC, whereas the メ-fetoprotein test, which is currently used to detect HCC, correctly identified only 25% of early-stage HCC patients. These results demonstrate that USP44 MS-HRM analysis is suitable for HCC surveillance.
Abstract, Accepted Manuscript(in press) [Submitted on July 13, 2022, Accepted on August 1, 2022]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd